Gsk PLC (GLAXF) — SEC Filings
Gsk PLC (GLAXF) — 35 SEC filings. Latest: 6-K (Dec 23, 2025). Includes 35 6-K.
Overview
Gsk PLC (GLAXF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 23, 2025: GSK plc announced on December 19, 2025, an agreement with the U.S. government to lower drug prices and expand access to its respiratory medicines for millions of Americans. This initiative aims to make essential treatments more affordable and accessible across the United States.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 35 neutral. The dominant filing sentiment for Gsk PLC is neutral.
Filing Type Overview
Gsk PLC (GLAXF) has filed 35 6-K with the SEC between Nov 2025 to Dec 2025.
Recent SEC Filings (35)
| Date | Form | Description | Risk |
|---|---|---|---|
| Dec 23, 2025 | 6-K | GSK to Lower Drug Prices, Expand US Access | low |
| Dec 22, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 19, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 18, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 17, 2025 | 6-K | 6-K Filing | |
| Dec 16, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 15, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 12, 2025 | 6-K | GSK Buys Back Own Shares | low |
| Dec 11, 2025 | 6-K | 6-K Filing | |
| Dec 10, 2025 | 6-K | GSK'227 Gets FDA Orphan Drug Nod for Lung Cancer | low |
| Dec 9, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 8, 2025 | 6-K | 6-K Filing | |
| Dec 5, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 4, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Dec 3, 2025 | 6-K | GSK Buys Back Own Shares Via BNP Paribas | low |
| Dec 2, 2025 | 6-K | 6-K Filing | |
| Dec 1, 2025 | 6-K | GSK plc Buys Back Own Shares | low |
| Nov 28, 2025 | 6-K | 6-K Filing | |
| Nov 26, 2025 | 6-K | 6-K Filing | |
| Nov 25, 2025 | 6-K | GSK Buys Back Own Shares | low |
Risk Profile
Risk Assessment: Of GLAXF's 21 recent filings, 0 were flagged as high-risk, 0 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Top Tags
share-buyback (15) · transaction (7) · transaction-in-own-shares (6) · share-repurchase (4) · company-news (3) · sec-filing (2) · pricing (1) · access (1) · government-agreement (1) · respiratory-medicine (1)
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Gsk PLC (GLAXF)?
Gsk PLC has 35 recent SEC filings from Nov 2025 to Dec 2025, including 35 6-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GLAXF filings?
Across 35 filings, the sentiment breakdown is: 35 neutral. The dominant sentiment is neutral.
Where can I find Gsk PLC SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Gsk PLC (GLAXF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Gsk PLC?
Financial highlights for Gsk PLC are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for GLAXF?
Investment thesis data for GLAXF will be available once enriched filings are processed.
Who are the key executives at Gsk PLC?
Executive information for Gsk PLC is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Gsk PLC stock?
Of GLAXF's 21 assessed filings, 0 were flagged high-risk, 0 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Gsk PLC?
Forward guidance and predictions for Gsk PLC are extracted from SEC filings as they are enriched.